Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNONW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings for Tenon Medical, Inc. (TNONW), a medical device company focused on a minimally invasive sacroiliac (SI) joint implant approach. The company’s filings, such as Forms 8-K, describe material events, corporate governance actions, and details about its capital structure, including warrants and equity incentive plans.
Tenon Medical, Inc.’s SEC filings include disclosures about its 2025 Annual Meeting of Stockholders, where stockholders voted on the election of directors, the exercisability of Series C-1 and Series C-2 Warrants, amendments to the 2022 Equity Incentive Plan, and ratification of the company’s independent auditor. These documents explain how the company manages equity-based compensation, share reserves, and warrant terms that may affect holders of its securities, including warrants trading under the symbol TNONW on The Nasdaq Stock Market LLC.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q (when filed), users can review discussions of Tenon Medical’s medical device business, risk factors, and financial statements. Current reports on Form 8-K highlight specific events such as stockholder meetings, changes to equity plans, and other significant developments. For investors tracking ownership changes, insider transaction reports on Form 4, when available, provide details on purchases, sales, or grants involving the company’s equity securities.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, such as warrant terms, equity plan amendments, and voting results. Real-time updates from the SEC’s EDGAR system help users see new filings as they appear, while AI explanations make complex regulatory language more accessible for readers analyzing Tenon Medical, Inc.’s disclosures.
Tenon Medical, Inc. files its annual report describing a niche medical device business focused on sacroiliac joint fusion, built around its Catamaran and SImmetry+ implant systems, both cleared by the FDA as Class II devices.
The company highlights a U.S. market opportunity it estimates at 270,000 procedures annually, or about $2.1 billion, and reports 11,296,378 common shares outstanding as of March 27, 2026. It emphasizes clinical data from its Mainsail and EVoluSIon studies and a sizable patent portfolio extending to around 2031.
Financially, Tenon discloses a going concern warning, a November 2025 PIPE that raised roughly $2.7 million net on 2,217,904 shares and matching warrants, and March 2026 convertible notes with about $5.2 million principal for $4.3 million proceeds. It also reports a Nasdaq minimum bid-price deficiency, with a compliance period running to August 24, 2026, and outlines extensive reimbursement, regulatory, and competitive risks.
Tenon Medical, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Fourth quarter 2025 revenue reached $1.5 million, up 92% from $0.8 million a year earlier, with gross profit of $1.0 million and gross margin improving to 69% from 46%.
For the year ended December 31, 2025, revenue was $3.9 million, a 20% increase from $3.3 million, and gross profit was $2.4 million, or 60% of revenue, up from $1.7 million and 52%. Operating expenses for 2025 were $15.2 million, roughly flat with $15.5 million in 2024, leading to a narrower net loss of $12.6 million, or $1.70 per share, compared with a $13.7 million loss, or $11.26 per share. Cash and cash equivalents were $3.8 million as of December 31, 2025, down from $6.5 million, and the company reported no debt. Management highlighted FDA 510(k) clearance and initial procedures for its next-generation SImmetry+ SI Joint Fusion System as key milestones supporting future growth.
Tenon Medical, Inc. has been notified by Nasdaq that its common stock failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days between January 9 and February 24, 2026, triggering a deficiency under Nasdaq’s bid price rule.
The company has 180 calendar days, until August 24, 2026, for its stock to close at or above $1.00 for at least 10 consecutive business days to regain compliance. If it still fails, Tenon may qualify for an additional 180-day period if it meets other Nasdaq listing standards and formally indicates how it plans to cure the deficiency, potentially through a reverse stock split.
Tenon’s shares continue to trade on The Nasdaq Capital Market under the symbol “TNON” while the company evaluates its options. However, failure to regain or maintain compliance could ultimately lead to delisting, though the company would have the right to appeal any delisting determination.
Tenon Medical, Inc. reported preliminary unaudited revenue ranges showing strong growth for 2025. Fourth quarter 2025 revenue is expected between $1.45 million and $1.48 million, which the company says is about 90% higher year over year compared with the fourth quarter of 2024.
For full year 2025, Tenon expects unaudited revenue between $3.91 million and $3.94 million, representing roughly 20% year-over-year growth versus 2024. The company plans to release full financial results after market close on March 19, 2026 and will host a conference call that day at 4:30 p.m. Eastern Time to discuss the results in more detail.
Tenon Medical, Inc. filed an 8-K dated September 23, 2025 that lists its publicly traded securities and records signatures and share-count figures for several named officers and directors. The document references Common Stock (par value $0.001) trading under the symbol TNON and Warrants trading under TNONW on The Nasdaq Stock Market. Individual entries show numeric holdings for Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle, and the filing is executed by Steven M. Foster in his capacity as Chief Executive Officer and President.
Tenon Medical, Inc. has rescheduled its previously adjourned Annual Meeting to be held virtually on September 18, 2025, at 10:30 a.m. Pacific Time. The meeting had been adjourned on July 23, 2025 and August 20, 2025.
Only shareholders of record at the close of business on August 22, 2025 are entitled to notice and to vote. Stockholders must use a Virtual Control Number to participate and vote electronically, with additional steps required for those holding shares in “street name.” The company urges shareholders to vote before September 16, 2025 to ensure their votes are received and counted.